Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 30;14(2):200.
doi: 10.3390/life14020200.

Novel Magnetic Resonance Imaging Tools for Hypertrophic Cardiomyopathy Risk Stratification

Fahad Alajmi  1 , Mehima Kang  1 , James Dundas  2   3 , Alexander Haenel  1 , Jeremy Parker  1 , Philipp Blanke  1   2 , Fionn Coghlan  1 , John King Khoo  1 , Abdulaziz A Bin Zaid  1 , Amrit Singh  4 , Bobby Heydari  1 , Darwin Yeung  1 , Thomas M Roston  1 , Kevin Ong  1 , Jonathon Leipsic  2 , Zachary Laksman  1
Affiliations
Review

Novel Magnetic Resonance Imaging Tools for Hypertrophic Cardiomyopathy Risk Stratification

Fahad Alajmi et al. Life (Basel). .

Abstract

Hypertrophic cardiomyopathy (HCM) is a common genetic disorder with a well described risk of sudden cardiac death; however, risk stratification has remained a challenge. Recently, novel parameters in cardiac magnetic resonance imaging (CMR) have shown promise in helping to improve upon current risk stratification paradigms. In this manuscript, we have reviewed novel CMR risk markers and their utility in HCM. The results of the review showed that T1, extracellular volume, CMR feature tracking, and other miscellaneous novel CMR variables have the potential to improve sudden death risk stratification and may have additional roles in diagnosis and prognosis. The strengths and weaknesses of these imaging techniques, and their potential utility and implementation in HCM risk stratification are discussed.

Keywords: T1; T2; cardiac magnetic resonance imaging; feature tracking; hypertrophic cardiomyopathy; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
A flow diagram for review methodology.
Figure 2
Figure 2
Kaplan–Meier curves from Li et al. [16] demonstrating survival free from events for the primary endpoint (composite of CV death, heart transplant, aborted SCD, and syncope requiring CPR) in KM curve (a), and for the secondary endpoint (heart failure hospitalizations) in KM curve (b), for subjects with ECV > 2 SD above mean (green curve) vs. those with ECV ≤ 2SD above mean (blue curve) (reproduced with permission).
Figure 3
Figure 3
Scatter plot from Chen et al. [20] demonstrating the association between the percentage of myocardium with a T2 signal and the degree of hs-cTnT level elevation. (Reproduced with permission). Medicine (Baltimore). 2020 Jun 5; 99(23): e20134. Published online 2020 Jun 5. doi: 10.1097/MD.0000000000020134. Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. Creative Commons Attribution License 4.0 (CCBY).
See this image and copyright information in PMC

References

    1. Makavos G., Κairis C., Tselegkidi M.E., Karamitsos T., Rigopoulos A.G., Noutsias M., Ikonomidis I. Hypertrophic cardiomyopathy: An updated review on diagnosis, prognosis, and treatment. Heart Fail. Rev. 2019;24:439–459. doi: 10.1007/s10741-019-09775-4. - DOI - PubMed
    1. Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R., Basso C., Bezzina C.R., Biagini E., Blom N.A., de Boer R.A., et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur. Heart J. 2023;44:3503–3626. doi: 10.1093/eurheartj/ehad194. - DOI - PubMed
    1. Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A., Charron P., Corrado D., Dagres N., de Chillou C., et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022;43:3997–4126. doi: 10.1093/eurheartj/ehac262. - DOI - PubMed
    1. Jazayeri M.A., Emert M.P. Sudden Cardiac Death: Who Is at Risk? Med. Clin. N. Am. 2019;103:913–930. doi: 10.1016/j.mcna.2019.04.006. - DOI - PubMed
    1. Writing Committee Members. Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P., Evanovich L.L., Hung J., Joglar J.A., et al. Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. [(accessed on 30 November 2022)];Circulation. 2020 142:E558–E631. Available online: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000937. - DOI - PubMed

LinkOut - more resources